High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

Yuanyan Tang†, Haisen Yin†, Xinying Zhao†, Dan Jin³, Yan Liang¹, Tao Xiong¹, Lu Li³, Wen Tang³, Jiangzhao Zhang¹, Min Liu¹, Zhuojun Yu¹, Huimin Liu¹, Sibin Zang¹ and Zhiping Huang¹*

Abstract

Background: B-cell maturation antigen (BCMA) chimeric antigen receptor T (CAR-T) cell therapy has obtained promising results in relapsed or refractory multiple myeloma (R/R MM), while some patients do not respond, or relapse in short term after treatment. Combining with anti-CD38 might solve the problem of targeting BCMA alone. We aimed to assess the efficacy and safety of BCMA and CD38 (BCMA-CD38) bispecific CAR-T cells in R/R MM patients.

Methods: We did a single-center, single-arm clinical study at the Second Affiliated Hospital of Yangtze University in China. Patients meeting with the inclusion criteria were administered with fludarabine and cyclophosphamide before CAR-T cells infusion. Response and adverse events were assessed after infusion. This study was registered with the Chinese Clinical Trial Registration Center (ChiCTR1900026286).

Results: First, we found BCMA-CD38 CAR-T cells exhibited enhanced killing effect on BCMA+CD38+ cells in vitro, compared to BCMA CAR-T and CD38 CAR-T cells. We further demonstrated its anti-tumor activity in vivo. Then, we enrolled 16 R/R MM patients for safety and efficacy analyses. Of the 16 evaluable patients, 14 (87.5%) respond to the treatment, including 13 stringent complete response (sCR) and one partial response (PR), while two patients did not respond. At a median follow-up of 11.5 months, of the 13 patients who achieved sCR, 76.9% (10/13) did not relapse or progress during follow-up. Relapse occurred in 3 patients (Patient 2, 3 and 4) after achieving sCR. In sum, four patients died, of which one died of hemophagocytic lymphohistiocytosis syndrome secondary to severe cytokine release syndrome (CRS) and three died of disease progression or relapse. The 1-year progression-free survival rates was 68.8%. The 1-year overall survival rate was 75.0%. Extramedullary lesions were eliminated in 62.5% (5/8) patients. The most common symptoms after CAR-T infusion were cytopenia (16, 100%), fever (10, 62.5%), fatigue (8, 50.0%) and myalgias (8, 50.0%). Twelve patients (75.0%) were observed with various grades of CRS, of which five patients (31.3%) got serious CRS (Grade ≥ 3). The CAR+ cell expansion levels were associated with the severity of CRS. Transient clonal isotype switch was observed after CAR-T infusion.

Conclusion: Our results confirm that BCMA-CD38 CAR-T cells therapy is feasible in treating R/R MM patients, with high response rate, low recurrence rate and manageable CRS, which will be a promising treatment option for R/R MM.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Multiple Myeloma (MM) is an almost incurable plasma cell malignancy, and most patients will eventually develop refractory disease and suffer a fatal relapse [1], in spite of the application of new drugs [2–4]. Recent studies have verified the activity of chimeric antigen receptor T (CAR-T) cell therapies in the treatment of relapsed or refractory MM (R/R MM), but the results established vastly different [5–7].

B-cell maturation antigen (BCMA), also known as CD269, is a member of the tumor necrosis factor superfamily, which is mainly expressed on plasma cells, and plasmacytoid dendritic cells, but not other normal cells, considered to be an ideal target for CAR-T cells in the treatment of R/R MM [8–10]. Many clinical trials of anti-BCMA CAR-T cell in R/R MM have been registered. Idecatagene Vicleucel (Idel-cel) has been approved for treating R/R MM, based on a phase II study that 73.4% of patients had a response and 31.3% had a complete response or better [11]. Ciltacabtagene autoleucel (Cilta-cel) is being reviewed with overall response rate (ORR) of 94.8%, stringent complete response (sCR) of 55.7%, and very good partial response rate (VGPR) of 32.0% [12]. However, the efficacy of targeting BCMA have showed promising but varied ORR ranging from 30 to 100%, or relapse occurs in a short time after CAR-T therapy, due to clonal evolution and loss of subclone in tumor cells, immunosuppression in bone marrow microenvironment, or exhaustion of CAR-T cells etc. [13, 14]. Besides anti-BCMA CAR-T cell therapy, anti-CD138, targeting κ light chains, or anti-NKG2D CAR-T therapy did not achieve an ideal efficacy in causing remission of R/R MM [15]. Despite many advantages compared to other CAR-T immunotherapy against R/R MM, anti-BCMA CAR-T therapy still need to further improve progression-free survival (PFS) and reduce side effects. It is expected that expanding the coverage of MM cells will achieve more favorable duration responses and less relapse by preventing single target ineffectiveness or overcoming BCMA negative relapse [18].

Daratumumab, as the first monoclonal antibody directly targeting MM cells, has been approved by the United States Food and Drug Administration for treating R/R MM. It has broad-spectrum killing activity, targeting the transmembrane extracellular enzyme CD38 molecule that highly expressed on the surface of MM cells, which can induce rapid apoptosis of tumor cells through a variety of mechanisms, prolong the survival of patients, and has no serious inhibition of myeloid cell growth [19]. Moreover, CD38 antigen has been optimized as a target of therapeutic CAR-T cells for MM in a preclinical study [20].

In this study, we first confirmed the enhanced killing effect of BCMA-CD38 CAR-T cells compared to BCMA CAR-T in vitro experiments, and further demonstrated its anti-tumor activity in vivo. On basis of these preliminary data, we recruited 16 R/R MM patients, aiming to detect the efficacy and safety of BCMA-CD38 CAR-T cells in R/R MM patients.

Methods

CAR-T production

The CAR fusion gene was inserted into third generation lentiviral cytoskeleton vector pLVX-EF1. pLVX-EF1 with CAR fusion gene, the helper plasmid and lentivirus packaging were co-transfected into HEK-293 T cells. The virus was then harvested and purified [21]. Peripheral blood mononuclear cells (PBMC) were isolated from 60 to 100 ml of peripheral blood collected from subjects by density gradient centrifugation (Ficoll Paque, GE life sciences). The initial cells were stimulated with CD3 and CD28 antibodies (0.5 μg/ml, R&D) and IL-2 (200 IU/ml, T&L) on day 0, then transduced with the CAR encoded lentivirus (MOI = 5:1) on day 2 to obtain CAR-T cells. After cultured for another 7 to 12 days, the cells were assessed by flow cytometry (FCM) of stained for BCMA-scFv with recombinant BCMA protein (rBCMA protein, ACRO) for transduction efficiency. The cells were also qualified evaluated for sterility, endotoxin and cell activity before infusion.

CAR-T function studies in vitro

To demonstrate the killing effect of CAR-T cells, we used an adherent cell line (BCMA+CD38+ Hela) for vitro experiments. BCMA+CD38+ Hela cells (1 × 10^4 per well) were seeded into the special culture in real-time unlabeled cell analysis (RTCA) system, with conductive electrode at the bottom of the culture plate. Three replicates were done for each sample. Eighteen hours after inoculation, tumor cells were quantitatively treated by T cells or CAR-T cells at different effective to target ratios (E:T) for another 42 h. The conductivity indices of the culture plates were collected every 30 min to record the relative numbers of tumor cells.
In vivo xenograft experiments
Four-week-old NOD-SCID mice (NOD-Prkdc<sup>scid</sup>, Il2rg<sup>null</sup>) were purchased from the National Resource Center for Rodent Laboratory Animals of China. BCMA+CD38+ K562 luciferase cells (2×10<sup>6</sup> each), which were suspended in 100μl of PBS, were administered to NOD-SCID mice via tail vein injection. On day 7, mice bearing engrafted tumors were randomized to treat with 2×10<sup>7</sup> mock-transduced T cells or BCMA-CD38 transduced T cells via tail-vein injection (n=6 each group). Tumor burden was monitored by bioluminescence imaging using an IVIS Lumina III LT Imaging System (PerkinElmer) on day 7, 14, and 28. The endpoint was either death of the mice or 36 days after injection. Peripheral blood and bone marrow samples were collected from all surviving mice for FCM tests. After lysis of red blood cells, GFP and anti-Human CD45 were used to label the tumor cells. All experiments were carried out as approved by the Institutional Animal Care and Use Committee of the Second Affiliated Hospital of Yangtze University.

Clinical trial design and participants
We did a single-center, single-arm, investigator initiated clinical study at the Second Affiliated Hospital of Yangtze University in China. This study was approved by the institutional independent ethics committee (reference number: 2017–010-02) of the Second Affiliated Hospital of Yangtze University in accordance with the Declaration of Helsinki, and was registered with Chinese Clinical Trial Registration Center (ChiCTR1900026286). All patients provided written informed consent. The primary objective is to evaluate the safety of BCMA-CD38 CAR-T cells, and the secondary objective is to evaluate the anti-myeloma response of the treatment.

Patients were eligible if they were 18–80 years of age, histologically confirmed MM, BCMA and CD38 positive confirmed by FCM, and met the International Myeloma Working Group (IMWG) diagnostic criteria for MM [22]. R/R MM patients should meet: treatment failure or disease progressed after 2 or more prior lines of treatment regimens, and disease progression or relapse is defined as IMWG. Adequate renal, hepatic, lung and heart function were required, and detailed definitions were described in Additional file 1. Previous BCMA or CD38 targeted cell therapy was not allowed. Detailed inclusion and exclusion criteria are provided in Additional file 1.

Procedures
All patients were confirmed as having MM after analysis of histology, immunology, imageological diagnosis, SPEP and UPEP, and had been categorized into different stages according to international stage system (ISS).

All patients underwent peripheral blood collection to obtain PBMC from which T cells were purified. After 9–14 days of CAR-T cells preparation, BCMA-CD38 CAR-T cells were infused. Three doses of fludarabine (25mg/m<sup>2</sup>) and cyclophosphamide (250mg/m<sup>2</sup>) were administered daily on days −4, −3 and −2 before CAR-T cells infusion. After the infusion of the engineered BCMA-CD38 CAR-T cells, all the patients were followed up at regular intervals.

Assessment
The objective is to evaluate the safety and efficacy of BCMA-CD38 CAR-T therapy in R/R MM. The evaluation of response was according to the IMWG criteria for response and minimal residual disease assessment in multiple myeloma (2016) [23], including sCR, complete response (CR), VGPR, partial response (PR), minimal response (MR), stable disease (SD), progression disease (PD). The response evaluation included the number of plasma cells in the bone marrow determined by morphology and minimal residual disease (MRD), FCM, serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free immunoglobulin light chains. Magnetic resonance imaging (MRI) or computed tomographic (CT) was employed to assess extramedullary involvement. Peripheral blood cells were collected at different time points to measure the percentages of CAR-T cells using FCM.

The cytokine release syndrome (CRS) was graded from 0 to 5 according to the Penn grading [24]. The severe CRS was defined as grade 3 or higher. In addition, interleukin-6 (IL-6), c-reactive protein (CRP) and ferritin were employed to help evaluate the severity of CRS.

Statistical analysis
We used student’s <i>t</i>-test to compared variable in vitro and in vivo experiments. The Mann-Whitney test was used to compare continuous variables.

Results
BCMA-CD38 bispecific CAR-T effectively lysed
BCMA+CD38+ tumor cells in vitro and in vivo studies
CAR was comprised of three main domains: a tumor associated antigen binding region, CD8α hinge and transmembrane region, and 4-1BB and CD3ζ intracellular motif (Fig. 1A). The CD38 antibody with 1000-fold reduced affinity was screened from plenty of CD38 antibodies with a broad range of different affinities. The CAR gene was exogenously expressed on the surface of CD3+ T cells. FCM analysis demonstrated that the proportion of CAR+ T cells on the 6th day of CD38, BCMA...
and BCMA-CD38 CAR virus infection could reach 31.42, 38.29 and 36.33%, respectively (Fig. 1B). The lysis effect of T cells, CD38 CAR-T cells, BCMA CAR-T cells and BCMA-CD38 CAR-T cells in vitro was recorded by conductive electrode at an E:T ratio of 0.5 and 2.5. BCMA+CD38+ Hela cells treated with BCMA-CD38 CAR-T cells were more severely suppressed, compared to BCMA CAR-T and CD38 CAR-T (Fig. 1C). CD38 CAR-T cells showed very weak killing effect for low affinity. Generally, more cytokines (IL-2, IL-6, IFN-γ and TNF-α) were detected in cells treated by BCMA-CD38 CAR-T cells, compared to BCMA CAR-T cells (Fig. 1D). These results demonstrated that BCMA-CD38 CAR-T cells exhibited stronger lyses effect than BCMA CAR-T cells and CD38 CAR-T cells. As for in vivo experiments, mice received 3 × 10⁶ T cells (n=6) and BCMA-CD38 CAR-T cells (n=6) 7 days after tumor cells injection, respectively. Bioluminescence imaging (BLI) showed a lower tumor burden in mice treated with BCMA-CD38 CAR-T cells as compared to T cells on d14 (P<0.001) and d28 (P=0.002) (Fig. 1E). During the experiment, we observed mild symptoms including lethargy, decreased activities and wrinkle in skin in two groups. And the symptoms of the two groups did not show much different, suggesting that there was no obvious CD38 off-target toxicity in xenograft models. By FCM analyses, tumor cells stained with GFP and anti-human CD45 of both PBMC (10.28% vs. 1.50%) and bone marrow cells (BMC) (52.63% vs. 0.04%) were significantly reduced in mice treated with BCMA-CD38 CAR-T cells, compared with those treated with T cells on d36. In contrast, T cells stained with anti-human CD45 on d36 rose to 49.83% in PBMC and 9.96% in BMC, respectively. To sum up, BCMA-CD38 bispecific CAR-T showed strong anti-tumor activity in vitro and in vivo. Hence, we then focus on investigating the safety and toxicity of BCMA-CD38 CAR-T in R/R MM patients.

**Patient characteristics**

To further demonstrate its efficacy in clinical, 16 R/R MM patients were enrolled (Supplementary Fig. 1). The study was initiated on May 20, 2018, and the cutoff date is Jun 1, 2020. The characteristics of the patients were list in Table 1. The patients had a median age of 58.5 (range 48–78) years old, and a median of 28.5 months (range 4–72) of disease duration before enrollment. The ISS stage of 81.3% (13/16) patients is stage III. Eight patients (50.0%) had extramedullary infiltration. Eleven patients (68.8%) have cytogenetic abnormalities including 1q21 (10/16, 62.5%), del17p (3/16, 18.8%), RB1 (1/16, 6.3%), and D13S319 (1/16, 6.3%). The median clonal sizes of Del17p and 1q21 were 20 and 25%, respectively. Clonal sizes of the cytogenetic abnormalities in detail were shown in Table 1. Three (18.8%) patients had received autologous hematopoietic stem cell transplantation (ASCT) before enrollment. The median percentages of MRD in BMC were 5.75%.

**BCMA-CD38 CAR-T was effective in alleviating intra- and extramedullary infiltration**

After a median of 12 days (9–14) of preparation, the total numbers of cultured cells reached a median number of 7.1 × 10⁶ (1.0–35.7 × 10⁶) (Table 2). The percentage of infusion T cells that expressed CAR-BCMA-CD38 was determined by FCM before infusion, ranging from 9.0 to 50.0% (Table 2). Median dose of CAR+ T cells were 2.1 × 10⁶/kg (0.5–10.0 × 10⁶/kg) (Table 2). A total dose of CAR-T cells was split into two or 3 days for infusion. According to IMWG 2016 criteria, we evaluate the response of patients (Fig. 2A), and obtained the best objective response (BOR) of every patient (Fig. 2B). Of the 16 evaluable patients, 14 (87.5%) had an overall response to the treatment, including 13 patients achieving a sCR and one patient achieving a PR, while two patients did not respond (Fig. 2B).
Fig. 1 (See legend on previous page.)
At data cut off, median follow-up was 11.5 months, ranging from 6.0 to 26.0 months. Of the 13 patients who achieved sCR, 76.9% (10/13) did not relapse or progress during follow-up. Relapse occurred in 3 patients (Patient 2, 3 and 4) after achieving sCR, and these events took place from 5 to 19 months after response (Fig. 2A). CAR-T cells exhaustion occurred in all the three recurrent patients. Patient 3 and 4 relapsed with BCMA and CD38 positive in bone marrow by FCM detection after 19 and 5 months, respectively (Fig. 2A). However, FCM detection suggested BCMA- and CD38+ in bone marrow of patient 2 after 16 months (Fig. 2A). In sum, four patients died, of which one (Patient 6) died of hemophagocytic lymphohistiocytosis syndrome (HLH) secondary to severe CRS and three died of disease progression or relapse (Fig. 2B). The Kaplan–Meier curve showed PFS rates of 68.8% at 12 months (Fig. 2C). The 1-year overall survival (OS) rate was 75.0% (Fig. 2D).

Eradication of plasma cells in bone marrow by CD38 staining in responders generally occurred in 1 month after CAR-T infusion ($P = 0.002$). Reduced level of monoclonal immunoglobulin (MIg) could be observed in 1 month after infusion ($P = 0.018$), while only one of them turned completely negative (Fig. 2E). It generally took a median of 2 (range from 1 to 10) months to get a negative MIg, longer than to eliminate myeloma cells in bone

### Table 1  Clinical Characteristics of patients with BCMA-CD38 CAR-T at baseline

| NO. | Age | Months of MM | Stage (ISS) | Subtype | EM | Cytogenetic abnormalities | Prior treatments | MRD (%) |
|-----|-----|--------------|-------------|---------|----|--------------------------|-----------------|---------|
| 1   | 62  | 6            | III         | κ       | No | 1q21 (9.0%)              | 2 BTZ           | No      |
| 2   | 60  | 60           | III         | IgA-λ   | No | 1q21 (14.0%), RB1 (13.0%), D13S319 (13.0%) | 3 BTZ Thal, Lenal, Pomal | Yes     |
| 3   | 50  | 18           | I           | IgG-κ   | No | 1q21 (31%), Del17p (13%)  | 2 BTZ           | Yes     |
| 4   | 78  | 72           | III         | IgA-λ   | Yes| 1q21 (26.0%), Del17p (20.0%) | 3 BTZ Thal, Lenal | No      |
| 5   | 70  | 66           | I           | κ       | No | Del17p (24.0%)            | 3 BTZ Lenal Thal | No      |
| 6   | 66  | 14           | III         | IgG-λ   | Yes| 1q21 (12%)               | 3 BTZ Lenal     | No      |
| 7   | 57  | 46           | III         | λ       | No | No                       | 3 BTZ Thal      | No      |
| 8   | 57  | 33           | III         | λ       | Yes| No                       | 3 BTZ Thal      | No      |
| 9   | 64  | 43           | III         | IgG-κ   | No | No                       | 3 BTZ Thal, Lenal | No      |
| 10  | 55  | 10           | III         | IgA-κ   | No | No                       | 2 BTZ           | No      |
| 11  | 74  | 4            | III         | IgA-κ   | Yes| No                       | 2 BTZ           | No      |
| 12  | 63  | 42           | III         | IgG-κ   | Yes| 1q21 (62.0%)             | 2 BTZ           | No      |
| 13  | 57  | 5            | III         | IgA-λ   | Yes| 1q21 (24.0%)             | 2 BTZ Thal      | No      |
| 14  | 53  | 39           | II          | IgG-λ   | Yes| 1q21 (27.0%)             | 3 BTZ Thal, Lenal Pomal | No      |
| 15  | 48  | 24           | III         | IgG-κ   | Yes| 1q21 (11.2%)             | 3 BTZ           | No      |
| 16  | 55  | 7            | III         | IgA-κ   | No | 1q21 (45.0%)             | 3 BTZ           | No      |

ISS International stage system, EM Extramedullary lesions, PI Proteasome inhibitor, IMID Immunomodulatory agents, ASCT Autologous hematopoietic stem cell transplantation, BTZ Bortezomib, THAL Thalidomide, Lenal Lenalidomide, Pomal Pomalidomide, MRD Minimal residual disease

### Table 2  Information of CAR-T cells in production

| NO. | Preparation days | T cells ($\times 10^8$) | Fraction of CAR+ T cells (%) | CAR+ T cells $\times 10^6$/kg |
|-----|------------------|-------------------------|-------------------------------|-------------------------------|
| 1   | 10               | 2.4                     | 18.0                          | 1.0                           |
| 2   | 12               | 35.7                    | 15.0                          | 10.0                          |
| 3   | 13               | 6.7                     | 9.0                           | 1.0                           |
| 4   | 12               | 5.6                     | 14.7                          | 1.6                           |
| 5   | 10               | 3.2                     | 18.0                          | 1.0                           |
| 6   | 10               | 15.7                    | 10.0                          | 2.7                           |
| 7   | 13               | 7.3                     | 30.0                          | 4.0                           |
| 8   | 13               | 24.7                    | 10.0                          | 4.1                           |
| 9   | 12               | 1.0                     | 30.0                          | 0.5                           |
| 10  | 12               | 10.7                    | 15.0                          | 2.1                           |
| 11  | 14               | 6.8                     | 15.0                          | 2.1                           |
| 12  | 14               | 9.5                     | 15.0                          | 2.0                           |
| 13  | 13               | 4.2                     | 18.0                          | 1.0                           |
| 14  | 11               | 3.6                     | 50.0                          | 3.0                           |
| 15  | 9                | 12.0                    | 20.0                          | 4.0                           |
| 16  | 10               | 16.5                    | 10.0                          | 2.9                           |
| Median | 12           | 7.1                     | 15.0                          | 2.1                           |
marrow (Fig. 2E). Our results thus indicated that the dual targeted CAR-T was effective in treating bone marrow infiltration of MM cells. The amplification after infusion at different times of CAR+ T cells in peripheral blood of response ≥ VGPR and response < VGPR patients were assessed by FCM. CAR-T cells levels in PBMC of patients usually reached a peak at 7 to 30 days (median 15d) after infusion, and CAR-T cells could be detected even 60 days after infusion (Fig. 2F). The peak CAR-T cell levels of patients who obtained anti-myeloma responses of sCR or VGPR (responders) were higher than the peak CAR-T cell levels of patients who obtained outcomes of SD or PD (P = 0.007), indicating higher blood CAR+ cell levels were associated with anti-myeloma response (Fig. 2F).

Before CAR-T cell infusion, all the patients underwent imaging evaluation. Extramedullary disease was observed in eight patients, and tumor mass in five patients (5/8, 62.5%) was eliminated (Fig. 3A-D, Fig. 6D). As seen on CT imaging, the tumor lesion on the right forehead of patient 4 (Fig. 3A), behind the trachea and within the mediastinum of patient 6 (Fig. 6D), on the thoracic wall of patient 8 and 15 (Fig. 3B and D), next to the sacrum of patient 12 (Fig. 3C) eliminated after CAR-T infusion. Besides, the bone destructions adjacent to these lesions were better repaired than before. Note that masses of the five patients above gradually disappeared were posterior to achieving undetectable MRD. Despite that tumor burden in bone marrow was relieved rapidly 1 month after CAR-T therapy, extramedullary lesions in ethmoid sinus of patient 14 did not eradicate (Supplementary Fig. 2A). Extramedullary infiltration of patient 11 and 13 did not eliminated due to poorly respond to CAR-T therapy (Supplementary Fig. 2B and C). These results demonstrated that BCMA-CD38 CAR-T showed strong activity in eliminating intra- and extramedullary involvement, which also resulted in adjacent bone destruction repaired.

**CRS and its influence factors**

We analyzed our cohort to search that 12 patients (75.0%) were observed with various grades of CRS, of which 5 patients (31.3%) had a serious CRS of Grade 3 or more, and one patient (Patient 6) died of severe CRS (Supplementary Table 1, Fig. 4B). Starting day of CRS symptoms typically varied from d0 to d15 (median d3), and can persist 2 to 45 days (median 11.5 d) (Supplementary Table 1). The most common symptoms were fever (10, 62.5%), fatigue (8, 50.0%) and myalgias (8, 50.0%), followed by migratory arthralgia (5, 31.3%), ostealgia (4, 25.0%), gastrointestinal symptoms (3, 18.8%) and focal pain (3, 18.8%) (Fig. 4A). Six patients got infection within 2 months after infusion, of which 3 got lung infection, 1 got digestive infection, 1 got upper respiratory tract infection and 1 got septicemia. We have described the above results in adverse events (Fig. 4A and Supplementary Table 1). Dyspnea, dizzy, numb, liver dysfunction and coagulopathy were also found (Fig. 4A). A high incidence of hematological toxicity was observed in our study (Supplementary Table 2), with 15 (93.8%) patients developing grade 3–5 leukopenia, 6 (37.5%) developing grade 3–4 anemia, and 4 (25.0%) developing grade 3–4 thrombocytopenia. Most of the toxicity was manageable, with three patients being treated with steroids, 11 patients being treated with nonsteroidal anti-inflammatory drugs (NSAIDs), and nine patients being treated with anti-infection. The detailed treatment of CRS was displayed in Supplementary Table 1. However, patient 6 suffered HLH secondary to severe CRS, which is described in detail in Fig. 6. We also measured peak cytokine levels to help evaluated CRS, identifying higher value of IL-6 (P = 0.038), Ferritin (P = 0.013) and CRP (P = 0.002) were observed in CRS grade ≥ 3 (Fig. 4C). We established that β2 microglobulin (β2-MG) as a marker of tumor burden was higher in severe CRS group (P = 0.020). However, there is no significant difference of CD38+ or BCMA+ cells in bone marrow, MIg, and light chain between mild and severe CRS (Fig. 4D). These results suggested that β2-MG was an independent predictor of severe CRS. The amplification after infusion at different times of CAR+ T cells in peripheral blood of CRS ≥ 3 and CRS < 3 patients were assessed by FCM. The peak CAR-T cell levels of patients who had severe CRS (CRS ≥ 3) were higher than the peak CAR-T cell levels of patients who had mild CRS (P = 0.028), indicating the CAR+ cell levels were associated with the severity of CRS (Fig. 4E).

(See figure on next page.)

**Fig. 2** BCMA-CD38 CAR-T cells had potent activity against intramedullary lesion in MM patients. A The duration of response to BCMA-CD38 CAR-T in 16 cases was assessed according to IMWG 2016. B The best objective response (BOR) after BCMA-CD38 CAR-T infusion to the cut off data. C The PFS curves of patients after BCMA-CD38 CAR-T infusion. D The OS curves of patients after BCMA-CD38 CAR-T infusion. E Left: CD38 expression by FCM in bone marrow before and 1 month after CAR-T cell infusion was compared. Right: Serum MIg determined by SPEP before and 1 month after CAR-T cell infusion was compared. Wilcoxon matched-pairs signed rank test was used for statistical comparison. F Left: The amplification curves of CAR+ T cells in peripheral blood of patients (response ≥ VGPR) assessed by FCM; Middle: The amplification curves of CAR+ T cells in peripheral blood of patients (response < VGPR) assessed by FCM; Right: Peak values of CAR+ T cells in peripheral blood of patients assessed by FCM were compared between patients whose response ≥ VGPR and response < VGPR after CAR-T delivery.
Fig. 2 (See legend on previous page.)
Fig. 3  BCMA-CD38 CAR-T cells had potent activity against extramedullary lesions in MM patients. A - D The extramedullary lesions of patient 4 (A), 8 (B), 12 (C) and 15 (D) before and 2 months after BCMA-CD38 CAR-T infusion.

Fig. 4  CRS and its risk factors. A The adverse events after BCMA-CD38 CAR-T infusion. B The rates of different CRS grades. C The peak cytokine levels (IL-6, Ferritin and CRP) between CRS grade ≥ 3 and CRS grade <3 were compared. Mann-Whitney test was used for statistical comparison. D The risk factors (Mlg, β2MG, doses of CAR-T infusion, light chain, and the percentages of CD38+ and BMCA+ plasma in bone marrow) at baseline were compared between CRS grade ≥ 3 and CRS grade <3. Mann-Whitney test was used for statistical comparison. E The amplification curves and peak values of CAR+ T cells in peripheral blood of patients assessed by FCM were compared between CRS grade ≥ 3 and CRS grade <3 after CAR-T cells infusion. Mann-Whitney test was used for statistical comparison.
Fig. 4 (See legend on previous page.)
A clonal isotype switch (CIS) presented after CAR-T infusion

A CIS was defined as the appearance of a new serum monoclonal that differed from the original heavy or light chain detected at diagnosis. Patient 10 was diagnosed with IgA-κ subtype MM pre-CAR-T infusion as seen in Fig. 5A, and 3 months after CAR-T infusion her Mlg turned undetectable. Six months after CAR-T infusion, we observed an apparent abnormal protein band (APB) of IgG-κ type, distinct from the paraprotein present at diagnosis through SPEP analysis, without detectable MRD (Fig. 5A and B). With the passage of time, FCM did not detect bone marrow recurrence of myeloma, and this APB decreased gradually disappeared 9 months after CAR-T infusion. Our data have demonstrated

Fig. 5 One typical cases of patients treated with BCMA-CD38 CAR-T cells. SPEP (A) and FCM analysis (B) detecting CD269 and CD38 of Patient 10 before and after CAR-T infusion
Severe CRS resulted in HLH in Patient 6. A) CAR+ cells in PBMC of Patient 6 was tested by FCM before and after BCMA-CD38 CAR-T infusion. Curves of max value of temperature (Tmax) and CRP before and after CAR-T infusion was recorded. B) Curves of inflammatory factors (Ferritin, IL-6, and D2 polymer) of Patient 6 before and after BCMA-CD38 CAR-T infusion. C) Morphology and FCM analysis detecting CD269 and CD38 staining of BMC of Patient 6 before, 1 and 2 months after BCMA-CD38 CAR-T infusion. D) The extramedullary lesion images of Patient 6 before and 2 months after BCMA-CD38 CAR-T infusion. E) White blood cells (WBC), hemoglobin (HGB) and platelet (PLT) levels of Patient 6 before and after BCMA-CD38 CAR-T infusion.
that a CIS is a benign phenomenon in course of CAR-T infusion.

Severe CRS resulted in HLH
Patient 6 received 8 courses of therapy, but her disease progressed prior to enrollment. At the time of enrollment, she had IgG-λ subtype MM for 14 months. Poor prognostic cytogenetics (1q21) were detected through fluorescence in situ hybridization (FISH) (Table 1). There were 32.21% abnormal plasma cells (morphology assessment) in bone marrow tissue, as well as absence of normal cells (Fig. 6C). The patient eventually died of septic shock. Taken together, severe CRS might lead to life threatening HLH.

Discussion
Idel-cel and Cilta-cel had a response of 73.4 and 94.8%, respectively [11] [12]. A meta-analysis was performed to determine the safety and clinical efficacy of BCMA CAR-T cell therapy in multiple myeloma, including 640 patients in twenty-three different CAR-T-cell products. The pooled overall response rate was 80.5% (73.5–85.9%), median progression-free survival (PFS) was 12.2 (11.4–17.4) months, and CRS was observed in 80.3% (69.0–88.2%) [25]. The BCMA CAR-T has shown remarkable curative potential against advanced R/R MM, but multiple trials have also reported recurrence or treatment failures with many promising avenues for improvement [26–28]. The combination with targeting CD38 is potential to make up the shortfall. Here, we constructed a dual-targeted CAR-T capable of targeting BCMA and CD38, which showed stronger lyses effect than BCMA CAR-T cells in vitro experiments. We further confirmed a high clinical efficacy of the bispecific CAR-T with an ORR of 87.5%, 1-year PFS rates of 68.8%, and a moderate and manageable CRS of 75.0%. Despite of higher ORR, it could not be concluded that BCMA-CD38 CAR-T cells had better efficacy, due to limited cases and no randomized controlled trial study of head to head.

CD38 is low expressed on the surface of precursor lymphocytes, myeloid cells and some non-hematopoietic tissues, but highly expressed on the surface of MM cells, which motivates the development of anti-CD38 CAR-T therapy [8, 29, 30]. The widely expressed characteristic of CD38 not only makes anti-CD38 CAR-T with high affinity have strong anti-MM effects, but also target-off effects against normal tissues, indicating that CD38 is a less ideal target. We achieved a 1000-fold reduced affinity antibody, through screening from plenty of CD38 antibodies with a broad range of different affinities. Here, we designed a CAR-T carrying anti-BCMA and the low affinity anti-CD38. In addition, it is more difficult for anti-CD38 activating immunological synapse response to the target cells, due to that anti-CD38 was at external part of the anti-BCMA on the protein spatial structure. As a result, the bispecific CAR-T have the characteristics of rapid combination and reconciliation, which will make the CAR-T have no or very weak killing effect on CD38+ cells. Anti-CD38 was used for auxiliary targeting and enhancing binding to anti-BCMA, rather than killing tumor cells directly. As to the adverse event in our study, we found mild gastrointestinal symptoms, tachycardia and myalgia, which might be related with the off-target effect. However, it is difficult to tell whether it is caused by tumor target-off effect or by CRS.

Oligoclonal immunoglobulin bands differing from those originally identified at diagnosis termed CIS has been reported in 26.4–43% patients with MM after high-dose chemotherapy or ASCT [31–34], showing that patients observed with an apparent APB had a significantly better survival. Besides, relapsed patients had disease characterized by the same type of paraprotein as that detected at diagnosis [31]. In our results, the patient 10 suffered a temporary CIS, but did not relapse.
Thus, our findings indicated that CAR-T might result in APB. However, the origin of the new monoclonal bands remains largely unknown. Gene sequencing of heavy chain variable region in 7 patients with post-ASCT CIS did not show a clonal relationship to the original malignant clone isotype, highlighting nonmalignant B cells as the likely origin of CIS [35]. Multiple studies have demonstrated that greater rates of MGUS correlated with immune system hyperactivation in patients with autoimmune disease, infection, or inflammatory or allergic disorders and after myeloablative regimens in recipients of an allograft when humoral reconstitution has occurred in a clonally deregulated pattern [36, 37]. The emerging of Mlg especially a new serum monoclonal is not always a sign of recurrence in MM, which should be distinguished from CIS at the same time. To the best of our knowledge, CIS after CAR-T infusion has not been reported before. Further investigations to define whether CIS might serve as an immune biomarker in CAR-T treatment and better understand the underlying mechanism will help to define a subset of patients most likely to benefit from immunotherapy.

Most CRS cases were mild and manageable, however one of them died of HLH. HLH is potentially fatal syndrome of immune hyperactivation, observed in about 1% of all patients treated with CAR-T therapy [38]. The hemocytopenia of acquired HLH is caused by excessive activation of macrophages and T lymphocytes by CRS in CAR-T treatment. Thus, CRS and HLH might belong to a similar spectrum of hyperinflammatory. Patients with HLH may have clinical features including high fever, multi-organ dysfunction, high ferritin levels of >10,000 ng/mL, CRS grade ≥3, hemophagocytosis in the bone marrow or hemocytopenia [39]. Cytokine-directed therapy, corticosteroids and other supportive therapy were the preferred treatment for refractory HLH [40]. There is still no evidence to support the use of etoposide and cytarabine in CAR-T related HLH. The treatment to CAR-T cell related HLH needed more study to meet the challenge.

Conclusions
In summary, we described here a promising strategy for the treatment of MM by targeting BCMA and CD38, which present a valid solution to the challenge of antigen escape in BCMA CAR-T therapy. Since the study was an exploratory one, later-registration clinical studies are being planned and designed, which will further demonstrate its efficacy and safety.

Abbreviations
APB: Abnormal protein band; ASCT: Autologous hematopoietic stem cell transplantation; BCMA: B-cell maturation antigen; BMC: Bone marrow cells; BCMA-CD38: BCMA and CD38; BOR: Best objective response; CAR-T: Chimeric antigen receptor T; CIS: Clonal Isotype Switch; CR: Complete response; CRP: C-reactive protein; CRS: Cytokine release syndrome; CT: Computed tomographic; FCM: Flow cytometry; FISH: Fluorescence in situ hybridization; HLH: Hemophagocytic lymphohistiocytosis syndrome; IL-6: Interleukin-6; IMWG: International Myeloma Working Group; ISS: International stage system; NSAIDs: Nonsteroidal anti-inflammatory drugs; MDSC: Myeloid-derived suppressor cells; MM: Multiple myeloma; Mlg: Monoclonal immunoglobulin; MR: Minimal response; MRD: Minimal residual disease; MRI: Magnetic resonance imaging; ORR: Overall response rate; OS: Overall survival; PBMC: Peripheral blood mononuclear cells; PD: Progression disease; PFS: Progression-free survival; PR: Partial response; R/R MM: Relapsed or refractory multiple myeloma; sCR: Stringent complete response; SD: Stable disease; SPEP: Serum protein electrophoresis; UPEP: Urine protein electrophoresis; VGPR: Very good partial response rate; β2-MG: β2 microglobulin.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13046-021-02214-z.

Acknowledgements
The authors would like to thank the study participants, and their families for support this study.

Authors' contributions
ZPH, YYT, DJ and LL designed the study. HSY and XXZ wrote the first draft of the manuscript. XYZ, YL, TX, JZZ, ML, ZJY, HML, and SBZ treated the patients and acquired data. HSY and XYZ analyzed the data. ZPH revised the manuscript. LL and WT test specimens of patients. The author(s) read and approved the final manuscript.

Funding
The study was funded by Health Commission of Hubei Province Scientific Research Project (WJ2019M81 and WJ2019F125).

Availability of data and materials
The data that support this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
The studies involving human participants were reviewed and approved by the institutional independent ethics committee (reference number: 2017-010-02) of the Second Affiliated Hospital of Yangtze University. The patients provided their written informed consent to participate in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare no conflicts of interest.

Author details
1 Department of Hematology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, No.60, Jingzhong Road, Jingzhou 434020, Hubei Province, China. 2Department of Gastroenterology, Key Laboratory,
of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Wuhan, China. 2Celytan Therapeutics Co. Ltd, Wuhan, China.

Received: 4 August 2021  Accepted: 7 December 2021
Published online: 03 January 2022

References

1. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101–19.
2. Jakubowiak A, Offidani M, Pegourie B, De La Rubia J, Garderet L, Laribi K, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127(23):2833–40.
3. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354(19):2079–80.
4. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Bekscak M, et al. Daratumumab, Bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66.
5. Sadelaia M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545(7655):423–31.
6. June CH, Sadelaia M. Chimeric antigen receptor therapy. N Engl J Med. 2016;375(1):164–72.
7. Cellyan Therapeutics Co. Ltd, Wuhan, China.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.